Podcasts about Morpho

In this episode, we're joined by Paul Frambot, Co-founder and CEO of Morpho Labs to discuss Morpho V2! We dive into Morpho V2's architecture, MEV implications for the new design, and the curator market. We also cover stablecoin demand, and the potential for building an onchain yield curve.Thanks for tuning in! -- Resources Morpho - Ushering in DeFi's Next Era: https://youtu.be/smvV7Ax3bdE Morpho V2: Liberating the Potential of Onchain Loans: https://morpho.org/blog/morpho-v2-liberating-the-potential-of-onchain-loans/ -- Katana is a DeFi-first chain built for deep liquidity and high yield. No empty emissions, just real yield and sequencer fees routed back to DeFi users.  Pre-deposit now: Earn high APRs with Turtle Club https://app.turtle.club/campaigns/katana or spin the wheel with Katana Krates https://app.katana.network/krates -- Ledger, the global leader in digital asset security, proudly sponsors Bell Curve! As Ledger celebrates 10 years of securing 20% of global crypto, it remains the top choice for securing your assets. Buy a LEDGER™ device now, and build confidently, knowing your BTC, ETH, SOL, and more are safe. Buy now on https://shop.ledger.com/?r=1da180a5de00. -- Citrea is the first zero-knowledge rollup to enhance the capabilities of Bitcoin blockspace and enable Bitcoin applications (₿apps). Citrea is optimistically verified by Bitcoin, offering the most Bitcoin-secured and native way to extend BTC's utility to DeFi.  Learn more about Citrea: https://citrea.xyz/?utm_source=bellcurve&utm_medium=podcast&utm_campaign=website_promo  Follow Citrea on X/Twitter for the latest on its journey to mainnet: https://x.com/citrea_xyz -- Grab your tickets to Permissionless IV. Use code BELL10 for 10% off: https://blockworks.co/event/permissionless-iv -- Follow Paul: https://x.com/PaulFrambot Follow MonetSupply: https://x.com/MonetSupply Follow Mike: https://x.com/MikeIppolito_ Subscribe on YouTube: https://bit.ly/3R1D1D9 Subscribe on Apple: https://apple.co/3pQTfmD Subscribe on Spotify: https://spoti.fi/3cpKZXH Get top market insights and the latest in crypto news. Subscribe to Blockworks Daily Newsletter: https://blockworks.co/newsletter/ Join the Bell Curve Telegram group: https://t.me/+nzyxAvQ0Xxc3YTEx -- Timestamps: (0:00) Introduction (1:20) Overview of Morpho (3:48) Why Hasn't Fixed Rate Lending Taken Off? (8:41) Borrower UX (12:03) Ads (Katana & Ledger) (12:42) Behind the Scenes of Fixed Rates (16:17) Improvements Made in Morpho v2 (20:15) Design Tradeoffs (29:36) Ads (Katana & Ledger) (30:44) MEV Implications (36:00) Term Preferences (44:25) Citrea Ad (45:00) The Curator Market (56:53) Vertical Integration Strategy (1:00:28) Stablecoin Demand (1:03:03) Building an Onchain Yield Curve -- Disclaimer: Nothing said on Bell Curve is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Mike, Jason, Michael, Vance and our guests may hold positions in the companies, funds, or projects discussed.

This week, Ryan and David unpack Circle's stunning IPO debut, soaring to a $25B market cap and triggering Wall Street's stablecoin frenzy. They break down the landmark Genius Act vote, bringing unprecedented regulatory clarity to stablecoins, and dive into Stripe's latest crypto bet, acquiring wallet innovator Privy. Polymarket goes mainstream in an official integration with Twitter, while SEC Chair Paul Atkins embraces DeFi as fundamentally American. Plus, Gemini quietly files for IPO, Plasma's billion-dollar Tether chain ignites, and Trump unexpectedly endorses crypto at Coinbase. ------

In this episode, we discuss Plasma's token sale, and whether USDT supply on Tron will migrate to Plasma. We also unpack Morpho's efforts to align token vs equity incentives. Finally, we dive into what products we are currently interested in and trying out. Thanks for tuning in! As always, remember this podcast is for informational purposes only, and any views expressed by anyone on the show are solely their opinions, not financial advice. Resources Building the Future of Global Payments: https://youtu.be/8Zd_MTSFojQ?feature=shared Axiom: Breaking Open the Trading Bot Market: https://x.com/defi_kay_/status/1920154686642139474 – Arkham is a crypto exchange and a blockchain analytics platform. Arkham allows crypto traders and investors to look inside the wallets of the best traders, largest funds and most influential players in crypto, and then act on that information.  Sign up to Arkham: https://auth.arkm.com/register?ref=blockworks  Eligibility varies by jurisdiction. Users residing in certain jurisdictions will be excluded from onboarding.  – Join us from June 24th-June 26th at Permissionless IV! Use code BELL10 at checkout for 10% off! Tickets: https://blockworks.co/event/permissionless-iv – Follow Carlos: https://x.com/0xcarlosg Follow Boccaccio: https://x.com/salveboccaccio Follow Danny: https://x.com/defi_kay_ Follow Blockworks Research: https://x.com/blockworksres Subscribe on YouTube: https://bit.ly/3foDS38 Subscribe on Apple: https://apple.co/3SNhUEt Subscribe on Spotify: https://spoti.fi/3NlP1hA Get top market insights and the latest in crypto news. Subscribe to Blockworks Daily Newsletter: https://blockworks.co/newsletter/ Join the 0xResearch Telegram group: https://t.me/+z0H6y2bS-dllODVh – Timestamps: (0:00) Introduction (3:26) Plasma's XPL Token Sale (12:48) Arkham Ad (13:14) Will Tron's USDT Supply Migrate to Plasma? (29:50) Arkham Ad (30:30) Morpho's Token Announcement (40:49) What New Products Are We Checking Out? (56:34) Come to Permissionless – Disclaimer: Nothing said on Bell Curve is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Mike, Jason, Michael, Vance and our guests may hold positions in the companies, funds, or projects discussed, and our guests may hold positions in the companies, funds, or projects discussed.

In this episode, we discuss Plasma's token sale, and whether USDT supply on Tron will migrate to Plasma. We also unpack Morpho's efforts to align token vs equity incentives. Finally, we dive into what products we are currently interested in and trying out. Thanks for tuning in! As always, remember this podcast is for informational purposes only, and any views expressed by anyone on the show are solely their opinions, not financial advice. -- Resources Building the Future of Global Payments: https://youtu.be/8Zd_MTSFojQ?feature=shared Axiom: Breaking Open the Trading Bot Market: https://x.com/defi_kay_/status/1920154686642139474 -- Accelerate your app development on Algorand with AlgoKit 3.0—now with native TypeScript and Python support, visual debugging, and seamless testing. Build, test, and deploy smarter with tools designed for speed and simplicity. Start building with AlgoKit today: https://algorand.co/algokit?utm_source=blockworkspodcast&utm_medium=banner&utm_campaign=algokit3&utm_id=algokit3&utm_term=algokit3 -- Ledger, the global leader in digital asset security, proudly sponsors 0xResearch! As Ledger celebrates 10 years of securing 20% of global crypto, it remains the top choice for securing your assets. Buy a LEDGER™ device now and build confidently, knowing your precious tokens are safe. Buy now on https://shop.ledger.com/?r=1da180a5de00. -- Marinade is the premier staking delegation platform on Solana, bringing billions in liquidity and security to the Solana network, and connecting SOL holders to the best staking rates.  Since launching in 2021, Marinade has expanded their suite of products to provide solutions for both DeFi users and TradFi, including liquid and native staking, as well as direct enterprise integrations.  To learn more about Marinade, follow the link below: https://marinade.finance/?utm_source=blockworks&utm_medium=partnerships&utm_campaign=podcast  -- Join us from June 24th-June 26th at Permissionless IV! Use Code 0x10 at checkout for 10% off! Tickets: https://blockworks.co/event/permissionless-iv -- Follow Carlos: https://x.com/0xcarlosg Follow Boccaccio: https://x.com/salveboccaccio Follow Danny: https://x.com/defi_kay_ Follow Blockworks Research: https://x.com/blockworksres Subscribe on YouTube: https://bit.ly/3foDS38 Subscribe on Apple: https://apple.co/3SNhUEt Subscribe on Spotify: https://spoti.fi/3NlP1hA Get top market insights and the latest in crypto news. Subscribe to Blockworks Daily Newsletter: https://blockworks.co/newsletter/ Join the 0xResearch Telegram group: https://t.me/+z0H6y2bS-dllODVh -- Timestamps: (0:00) Introduction (2:59) Plasma's XPL Token Sale (12:20) Ads (Algorand & Ledger) (13:06) Will Tron's USDT Supply Migrate to Plasma? (29:43) Ads (Algorand & Ledger) (30:52) Morpho's Token Announcement (41:10) Marinade Ad (41:42) What New Products Are We Checking Out? (57:28) Come to Permissionless -- Check out Blockworks Research today! Research, data, governance, tokenomics, and models – now, all in one place Blockworks Research: https://www.blockworksresearch.com/ Free Daily Newsletter: https://blockworks.co/newsletter -- Disclaimer: Nothing said on 0xResearch is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Boccaccio, Danny, and our guests may hold positions in the companies, funds, or projects discussed.

Morpho Labs introduces Morpho V2. Gelato introduces the Smart Wallet SDK. Spark announces its Ignition Airdrop. And Optimism announces Season 8 governance updates. Read more: https://ethdaily.io/719 Disclaimer: Content is for informational purposes only, not endorsement or investment advice. The accuracy of information is not guaranteed.

Get your Magic Mind here: https://magicmind.com/CHIPM20You get 20% off a one-time purchase and up to 48% off subscriptions with my code: CHIPM20In this episode of The Chip Mahoney Show, we dissect the collapse of SafeMoon, revealing the intricate web of fraud behind this once-promising cryptocurrency. Chip Mahoney contrasts the fraudulent aspects of SafeMoon with Morpho, a revolutionary DeFi protocol that is successfully providing real yield through its innovative on-chain vaults. Discover the implications of these contrasting projects in the ever-evolving world of crypto, blockchain, and Web3 technology. Whether you're a seasoned investor or new to the crypto space, this episode delivers critical insights into understanding fraud and recognizing genuine opportunities in the market. Front Run The Week: Want to catch the next big crypto move before it hits the headlines? Get my free newsletter at tokentrust.substack.com for exclusive early insights.The Chip Mahoney Show is a Big Pond production. This podcast is for entertainment and educational purposes only.For media inquiries or guest bookings, please contact:DV Collective at dvpodcastshow@gmail.comMusic licensed via Spotify Creator tools.

Morpho deploys on Unichain. Fluidkey launches the Fluidkey Score. Symbiotic introduces Relay. And the Devconnect Scholars Program opens applications. Read more: https://ethdaily.io/714 Disclaimer: Content is for informational purposes only, not endorsement or investment advice. The accuracy of information is not guaranteed.

Kedian Sun is the CoFounder at Level.In this episode, we dive into Level, a new stablecoin protocol offering yield lending USDC and USDT to blue-chip protocols, including how Level's design enables higher yields, what risks and tradeoffs come with that, and how stablecoin farmers can put lvlUSD to work across DeFi protocols like Pendle and Morpho.------

In this episode, Bell Curve kicks off its new season with Mippo and monetsupply outlining the major DeFi themes they'll be exploring. They dive into institutional adoption of DeFi, the increasing vertical integration by leading DeFi players, stablecoins and real-world assets, and the growing financialization of crypto, setting the stage for our best season yet! Thanks for tuning in! -- Namada is the shielded asset hub rewarding you to protect the multichain. Enabling data protection for any existing asset, app, or chain, Namada introduces shielded cross-chain actions and rewards for shielding your assets, which strengthens data protection guarantees for everyone. Namada is currently entering phase 3 of its mainnet launch — follow along on https://namada.net/ -- Ledger, the global leader in digital asset security, proudly sponsors Bell Curve! As Ledger celebrates 10 years of securing 20% of global crypto, it remains the top choice for securing your assets. Buy a LEDGER™ device now, and build confidently, knowing your BTC, ETH, SOL, and more are safe. Buy now on https://shop.ledger.com/?r=1da180a5de00. -- Citrea is the first zero-knowledge rollup to enhance the capabilities of Bitcoin blockspace and enable Bitcoin applications (₿apps). Citrea is optimistically verified by Bitcoin, offering the most Bitcoin-secured and native way to extend BTC's utility to DeFi.  Learn more about Citrea: https://citrea.xyz/?utm_source=bellcurve&utm_medium=podcast&utm_campaign=website_promo  Follow Citrea on X/Twitter for the latest on its journey to mainnet: https://x.com/citrea_xyz -- Join us from June 24th-June 26th at Permissionless IV! Use Code BELL10 at checkout for 10% off! Tickets: https://blockworks.co/event/permissionless-iv -- Follow MonetSupply: https://x.com/MonetSupply Follow Mike: https://x.com/MikeIppolito_ Subscribe on YouTube: https://bit.ly/3R1D1D9 Subscribe on Apple: https://apple.co/3pQTfmD Subscribe on Spotify: https://spoti.fi/3cpKZXH Get top market insights and the latest in crypto news. Subscribe to Blockworks Daily Newsletter: https://blockworks.co/newsletter/ Join the Bell Curve Telegram group: https://t.me/+nzyxAvQ0Xxc3YTEx -- Timstamps: (0:00) Introduction (2:50) What's Exciting About DeFi Today? (6:46) Fragmentation & Reaggregation in DeFi (14:03) Ads (Namada & Ledger) (14:37) Morpho vs Aave's Architecture (18:44) Counterparty Risks With Modular Designs (25:09) Vertical Integration in DeFi (34:35) DeFi Outside of Ethereum's Ecosystem (45:41) Ads (Namada & Ledger) (46:51) RWAs and Stablecoins (1:01:32) Citrea Ad (1:02:01) The Financialization of DeFi (1:12:50) How Does Stablecoin Growth Impact the L1? (1:18:25) The Cold Start Problem -- Disclaimer: Nothing said on Bell Curve is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Mike, Jason, Michael, Vance and our guests may hold positions in the companies, funds, or projects discussed.

In this episode, we're joined by Guy Young , Founder at Ethena Labs, to discuss the rapid growth of USDe, the design of their new products like USDtb, and the launch of Converge and Ethereal. He shares insights on stablecoin infrastructure, institutional adoption, risk management, and Ethena's broader vision to bridge DeFi with TradFi. Thanks for tuning in! As always, remember this podcast is for informational purposes only, and any views expressed by anyone on the show are solely their opinions, not financial advice. -- Resources Converge Technical Specification & Roadmap: https://x.com/convergeonchain/status/1912853619038461967 -- Arkham is a crypto exchange and a blockchain analytics platform. Arkham allows crypto traders and investors to look inside the wallets of the best traders, largest funds and most influential players in crypto, and then act on that information.  Sign up to Arkham: https://auth.arkm.com/register?ref=blockworks  Eligibility varies by jurisdiction. Users residing in certain jurisdictions will be excluded from onboarding.  -- Ledger, the global leader in digital asset security, proudly sponsors Bell Curve! As Ledger celebrates 10 years of securing 20% of global crypto, it remains the top choice for securing your assets. Buy a LEDGER™ device now, and build confidently, knowing your BTC, ETH, SOL, and more are safe. Buy now on https://shop.ledger.com/?r=1da180a5de00. -- Traders, AI enthusiasts, and degens—listen up! The game is changing, and DESK is leading the charge. Welcome to the next generation of perpetual trading—where cutting-edge technology meets AI-driven automation. Trade today at https://desk.exchange/?register-channel=BWpodcast and follow @TradeOnDESK on X! -- Missed DAS? Join us from June 24th-June 26th at Permissionless IV! Use Code BELL10 at checkout for 10% off! Tickets: https://blockworks.co/event/permissionless-iv -- Follow Converge: https://x.com/convergeonchain Follow Ethereal: https://x.com/etherealdex Follow Guy: https://x.com/gdog97_ Follow Boccaccio: https://x.com/salveboccaccio Follow Blockworks Research: https://x.com/blockworksres Subscribe on YouTube: https://bit.ly/3foDS38 Subscribe on Apple: https://apple.co/3SNhUEt Subscribe on Spotify: https://spoti.fi/3NlP1hA Get top market insights and the latest in crypto news. Subscribe to Blockworks Daily Newsletter: https://blockworks.co/newsletter/ Join the 0xResearch Telegram group: https://t.me/+z0H6y2bS-dllODVh -- Timestamps: (0:00) Introduction (1:41) Recent Product Launches (5:29) Asset Issuance on Converge (11:15) Ads (Arkham & Ledger) (11:53) Scaling Ethena (13:45) Considering New Assets For Staking Yield (15:58) Dealing With Risk (18:07) USDtb's Place in the Ethena Ecosystem (22:21) Ads (Arkham & Ledger) (23:30) Overview of Ethereal (26:26) Converge DApps (30:25) Credit Expansion and Associated Risks (33:12) Ads (Desk & Morpho) (34:07) Will Ethereal Harm Relationships With Exchanges? (36:12) Protocols Hardcoding USDe to 1$ (39:20) USDe's Competition (41:04) The Biggest Risks to Ethena (43:08) The Fee Switch (47:12) Ethena's Focus Going Forward -- Check out Blockworks Research today! Research, data, governance, tokenomics, and models – now, all in one place Blockworks Research: https://www.blockworksresearch.com/ Free Daily Newsletter: https://blockworks.co/newsletter -- Disclaimer: Nothing said on 0xResearch is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Boccaccio, Danny, and our guests may hold positions in the companies, funds, or projects discussed.

In this episode, we're joined by Paul Faecks, the Founder of Plasma, and Zaheer of Split Capital, to discuss Plasma, a blockchain focused solely on providing stablecoin infrastructure. We dive into why general-purpose chains aren't optimized for stablecoin settlement, Plasma's architecture and how they will mitigate spam, and the broader implications for global payments, regulation, and the stablecoin economy's future as trillions move onchain. Thanks for tuning in! As always, remember this podcast is for informational purposes only, and any views expressed by anyone on the show are solely their opinions, not financial advice. -- Aries Markets is the largest lending protocol on Aptos by TVL, and among the top 10 lending protocols across all blockchains! Since launch, Aries has expanded its product suite to become a fully integrated DeFi hub combining lending, borrowing, and more to its community of 738,000+ unique users.  To learn more about why Aries Markets deployed on Aptos, visit ariesmarkets.xyz -- Ledger, the global leader in digital asset security, proudly sponsors Bell Curve! As Ledger celebrates 10 years of securing 20% of global crypto, it remains the top choice for securing your assets. Buy a LEDGER™ device now, and build confidently, knowing your BTC, ETH, SOL, and more are safe. Buy now on https://shop.ledger.com/?r=1da180a5de00. -- Traders, AI enthusiasts, and degens—listen up! The game is changing, and DESK is leading the charge. Welcome to the next generation of perpetual trading—where cutting-edge technology meets AI-driven automation. Trade today at https://desk.exchange/?register-channel=BWpodcast and follow @TradeOnDESK on X! -- Missed DAS? Join us from June 24th-June 26th at Permissionless IV! Use Code BELL10 at checkout for 10% off! Tickets: https://blockworks.co/event/permissionless-iv -- Follow Plasma: https://x.com/PlasmaFdn Follow Paul: https://x.com/pauliepunt Follow Zaheer: https://x.com/SplitCapital Follow Boccaccio: https://x.com/salveboccaccio Follow Blockworks Research: https://x.com/blockworksres Subscribe on YouTube: https://bit.ly/3foDS38 Subscribe on Apple: https://apple.co/3SNhUEt Subscribe on Spotify: https://spoti.fi/3NlP1hA Get top market insights and the latest in crypto news. Subscribe to Blockworks Daily Newsletter: https://blockworks.co/newsletter/ Join the 0xResearch Telegram group: https://t.me/+z0H6y2bS-dllODVh -- Timestamps: (0:00) Introduction (3:16) Why Build Plasma? (11:07) The PMF For Stablecoins (15:32) Aptos Ad (15:46) Plasma's Architecture (22:43) HotStuff-Inspired Consensus (26:10) Aptos Ad (26:42) Zero Fees and Handling Spam (34:57) Competing With Tron (41:05) Ads (Desk & Morpho) (41:59) Variations of Stablecoins (46:52) Why Build on Bitcoin? (48:07) The Stablecoin Space Going Forward (1:00:45) Closing Comments -- Check out Blockworks Research today! Research, data, governance, tokenomics, and models – now, all in one place Blockworks Research: https://www.blockworksresearch.com/ Free Daily Newsletter: https://blockworks.co/newsletter -- Disclaimer: Nothing said on 0xResearch is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Boccaccio, Danny, and our guests may hold positions in the companies, funds, or projects discussed.

3 exemples de token qui ont réussi leur listing, 3 exemples de token dont le listing s'est moins bien passé : on a analysé avec Richard Hamelin, Web3 Investment Director au sein de 50Partners, quelques projets incontournables (Hyperliquid, Morpho, Pendle, Celestia, Berachain) qui ont lancé leur token.// BLOCKCHAIN BUSINESS SCHOOLUn grand merci à la Blockchain Business School de soutenir mon travail

In this episode, we discuss the market's reaction to Trump's tariff pivots, global trade tensions, and where stablecoins fit into all of it. We also explore the potential of crypto as the last truly global market, and why we believe the IPO & TGE window has closed. Thanks for tuning in! -- Arkham is a crypto exchange and a blockchain analytics platform. Arkham allows crypto traders and investors to look inside the wallets of the best traders, largest funds and most influential players in crypto, and then act on that information.  Sign up to Arkham: https://auth.arkm.com/register?ref=blockworks  Eligibility varies by jurisdiction. Users residing in certain jurisdictions will be excluded from onboarding.  -- Marinade is the premier staking delegation platform on Solana, bringing billions in liquidity and security to the Solana network, and connecting SOL holders to the best staking rates. Since launching in 2021, Marinade has expanded their suite of products to provide solutions for both DeFi users and TradFi, including liquid and native staking, as well as direct enterprise integrations.  To learn more about Marinade, follow the link below: https://marinade.finance/?utm_source=blockworks&utm_medium=partnerships&utm_campaign=podcast -- Traders, AI enthusiasts, and degens—listen up! The game is changing, and DESK is leading the charge. Welcome to the next generation of perpetual trading—where cutting-edge technology meets AI-driven automation. Trade today at https://desk.exchange/?register-channel=BWpodcast and follow @TradeOnDESK on X! -- Missed DAS? Join us from June 24th-June 26th at Permissionless IV! Use Code BELL10 at checkout for 10% off! Tickets: https://blockworks.co/event/permissionless-iv -- Follow Mike: https://twitter.com/MikeIppolito_ Follow Michael: https://twitter.com/im_manderson Follow Vance: https://twitter.com/pythianism Subscribe on YouTube: https://bit.ly/3R1D1D9 Subscribe on Apple: https://apple.co/3pQTfmD Subscribe on Spotify: https://spoti.fi/3cpKZXH Get top market insights and the latest in crypto news. Subscribe to Blockworks Daily Newsletter: https://blockworks.co/newsletter/ Join the Bell Curve Telegram group: https://t.me/+nzyxAvQ0Xxc3YTEx -- Timestamps: (0:00) Introduction (4:30) The Markets Going Forward (7:49) Separating Main Street From Wall Street (14:38) Ads (Arkham & Marinade) (15:12) The Trade Deficit & Stablecoin Demand (24:23) Global Trust in US Markets & AI 2027 (34:08) Ads (Arkham & Marinade) (35:21) Open Source Strategy (41:02) Stablecoin Legislation (44:11) Ads (Desk & Morpho) (45:06) The IPO & TGE Window is Closed (48:26) SPAC City (53:23) IBC Eureka Goes Live & Ripple Acquires Hidden Road (1:03:31) Crypto's Fundamental Transition -- Disclaimer: Nothing said on Bell Curve is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Mike, Jason, Michael, Vance and our guests may hold positions in the companies, funds, or projects discussed, and our guests may hold positions in the companies, funds, or projects discussed.

In this week's episode, we're joined by A.J. Warner, CSO at Offchain Labs, to discuss his bold vision for Arbitrum as a “digital sovereign nation.” We explore key differences between L1s and L2s, Arbitrum's business model, capital allocation strategies, and how the new OpCo structure will drive governance and operational efficiency. Enjoy! -- Resources Hope for the Future of Arbitrum: https://x.com/ajwarner90/status/1908143389658194094 Arbitrum Forum - OpCo: https://forum.arbitrum.foundation/c/dao-grant-programs/operation-company-opco/63 -- Namada is the shielded asset hub rewarding you to protect the multichain. Enabling data protection for any existing asset, app, or chain, Namada introduces shielded cross-chain actions and rewards for shielding your assets, which strengthens data protection guarantees for everyone. Namada is currently entering phase 3 of its mainnet launch — follow along on https://namada.net/ -- Ledger, the global leader in digital asset security, proudly sponsors Bell Curve! As Ledger celebrates 10 years of securing 20% of global crypto, it remains the top choice for securing your assets. Buy a LEDGER™ device now, and build confidently, knowing your BTC, ETH, SOL, and more are safe. Buy now on https://shop.ledger.com/?r=1da180a5de00. -- Traders, AI enthusiasts, and degens—listen up! The game is changing, and DESK is leading the charge. Welcome to the next generation of perpetual trading—where cutting-edge technology meets AI-driven automation. Trade today at https://desk.exchange/?register-channel=BWpodcast and follow @TradeOnDESK on X! -- Morpho is a permissionless lending platform that allows anyone to earn yield and borrow assets on your terms. Its flexible, trustless infrastructure also empowers developers and businesses to build and tailor their own financial products. Whether you're an individual, fund, fintech, or institution, Morpho is for you. Try Morpho today: https://app.morpho.org/?network=mainnet&spdl=99nsk9 -- Missed DAS? Join us from June 24th-June 26th at Permissionless IV! Use Code BELL10 at checkout for 10% off! Tickets: https://blockworks.co/event/permissionless-iv -- Follow AJ: https://x.com/ajwarner90 Follow Mike: https://x.com/MikeIppolito_ Subscribe on YouTube: https://bit.ly/3R1D1D9 Subscribe on Apple: https://apple.co/3pQTfmD Subscribe on Spotify: https://spoti.fi/3cpKZXH Get top market insights and the latest in crypto news. Subscribe to Blockworks Daily Newsletter: https://blockworks.co/newsletter/ Join the Bell Curve Telegram group: https://t.me/+nzyxAvQ0Xxc3YTEx -- Timestamps: (0:00) Introduction (2:20) Thinking About L1s vs L2s (10:15) Ads (Namada & Ledger) (10:49) L2s Ability to Allocate Capital (20:35) Arbitrum's Business Model (26:38) Ads (Namada & Ledger) (27:48) Key Growth Metrics (33:29) Capital Allocation Concerns & Arbitrum Governance (48:40) Ads (Desk & Morpho) (49:34) Arbitrum Stakeholders & DAO Structure (57:21) Operational Challenges & the Future of Arbitrum -- Disclaimer: Nothing said on Bell Curve is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Mike, Jason, Michael, Vance and our guests may hold positions in the companies, funds, or projects discussed.

In this episode, we break down Trump's proposed tariffs, their impact on global trade, and how markets are responding. We also explore Circle's IPO filing, stablecoin economics, distribution partner incentives, and whether stablecoins could disrupt traditional banking. The conversation wraps with insights into token launch strategy and timing. Thanks for tuning in! -- Resources Warp Speed w/ Hamilton Lane's Erik Hirsch: https://open.spotify.com/episode/0SXehDDyqPahTiECa81A3a?si=Zz3A7l5fTAi-CvGYPJkqnw&context=spotify%3Ashow%3A5mWMlenq9TcEZlgXey2qKY -- Namada is the shielded asset hub rewarding you to protect the multichain. Enabling data protection for any existing asset, app, or chain, Namada introduces shielded cross-chain actions and rewards for shielding your assets, which strengthens data protection guarantees for everyone. Namada is currently entering phase 3 of its mainnet launch — follow along on https://namada.net/ -- Marinade is the premier staking delegation platform on Solana, bringing billions in liquidity and security to the Solana network, and connecting SOL holders to the best staking rates. Since launching in 2021, Marinade has expanded their suite of products to provide solutions for both DeFi users and TradFi, including liquid and native staking, as well as direct enterprise integrations.  To learn more about Marinade, follow the link below: https://marinade.finance/?utm_source=blockworks&utm_medium=partnerships&utm_campaign=podcast -- Traders, AI enthusiasts, and degens—listen up! The game is changing, and DESK is leading the charge. Welcome to the next generation of perpetual trading—where cutting-edge technology meets AI-driven automation. Trade today at https://desk.exchange/?register-channel=BWpodcast and follow @TradeOnDESK on X! -- Morpho is a permissionless lending platform that allows anyone to earn yield and borrow assets on your terms. Its flexible, trustless infrastructure also empowers developers and businesses to build and tailor their own financial products. Whether you're an individual, fund, fintech, or institution, Morpho is for you. Try Morpho today: https://app.morpho.org/?network=mainnet&spdl=99nsk9 -- Missed DAS? Join us from June 24th-June 26th at Permissionless IV! Use Code BELL10 at checkout for 10% off! Tickets: https://blockworks.co/event/permissionless-iv -- Follow Mike: https://twitter.com/MikeIppolito_ Follow Michael: https://twitter.com/im_manderson Follow Vance: https://twitter.com/pythianism Subscribe on YouTube: https://bit.ly/3R1D1D9 Subscribe on Apple: https://apple.co/3pQTfmD Subscribe on Spotify: https://spoti.fi/3cpKZXH Get top market insights and the latest in crypto news. Subscribe to Blockworks Daily Newsletter: https://blockworks.co/newsletter/ Join the Bell Curve Telegram group: https://t.me/+nzyxAvQ0Xxc3YTEx -- Timestamps: (0:00) Introduction (1:32) Thoughts on Trump's Liberation Day (7:02) The Tariff Board (11:03) Ads (Namada & Marinade) (11:33) Markets React to Trump's Tariffs (24:17) Circle Files For an IPO (33:25) Ads (Namada & Marinade) (34:39) Thoughts on Circle's Business (42:40) Are Stablecoins Disruptive to Banks? (51:22) Ads (Desk & Morpho) (52:16) Could Circle Have Launched a Token? (57:04) When to Launch a Token -- Disclaimer: Nothing said on Bell Curve is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Mike, Jason, Michael, Vance and our guests may hold positions in the companies, funds, or projects discussed, and our guests may hold positions in the companies, funds, or projects discussed.

SummaryJonathan Libby from Gauntlet joins the ATX DAO Podcast to unpack his journey from DeFi founder to driving growth at one of the most influential firms in on-chain risk management. He shares how Gauntlet evolved from agent-based simulations and protocol consulting into a powerhouse that builds core infrastructure, including Morpho vaults and curated restaking strategies, while managing billions in TVL.In this episode, Jonathan breaks down how DeFi protocols can scale safely, what makes a DAO partnership compelling, and why applied research is key to the next wave of financial innovation. It is a deep dive into smart risk, real-world DeFi applications, and the mindset it takes to build at scale.Chapters00:00 Introduction to Crypto and DeFi05:35 The Journey of a Founder in DeFi14:48 Building and Scaling at Gauntlet26:53 Economic Safety Strategies for Protocols31:08 Symbiotic Alts and Risk Mitigation37:22 The Era of Financial Instrumentation43:14 Innovations in DeFi Products46:04 Building Relationships with DAOs51:36 Navigating Governance Risks in DAOsConnect with Jon and Gauntlet:X (Twitter): ⁠⁠Jon - @0xJibby | Gauntlet - @gauntlet_xyz | Morpho - @MorphoLabsTelegram: @jonathanLibbyLinkedIn: Jon Libby | GauntletGauntlet Website: https://www.gauntlet.xyzMorpho Website: https://app.morpho.org/ethereum/earnTo learn more about ATX DAO:Check out the ⁠ATX DAO ⁠websiteFollow ⁠@ATXDAO⁠ on X (Twitter)Subscribe to our newsletterConnect with us on ⁠LinkedIn⁠Join the community in the ⁠ATX DAO Discord⁠Connect with the ATX DAO Podcast team on X (Twitter):Ash:  ⁠@ashinthewild⁠Luke: ⁠⁠⁠⁠⁠@Luke152⁠⁠⁠⁠⁠Support the Podcast:If you enjoyed this episode, please leave us a review and share it with your network.Subscribe for more insights, interviews, and deep dives into the world of Web 3.

The Pectra hardfork is set for May 7th. Tim Beiko proposes an ACD calls restructuring. Morpho Labs introduces Prime. And WisdomTree brings its RWA platform onchain. Read more: https://ethdaily.io/677

In this episode, we're joined by Jacob Horne, Co-founder and CEO of Zora, to unpack the platform's journey thus far. We explore tokenized media, royalty models, and how crypto enables a new internet economy where content, attention, and value converge. We also dive into Zora's design, and features they're looking to add next. Thanks for tuning in! -- Resources The Evolution of Crypto Exchanges: https://apple.co/4aZcHnJ The PumpFun Episode: https://apple.co/4gvRjHU Jacob's Writings: https://jacob.energy/ -- Aries Markets is the largest lending protocol on Aptos by TVL, and among the top 10 lending protocols across all blockchains! Since launch, Aries has expanded its product suite to become a fully integrated DeFi hub combining lending, borrowing, and more to its community of 738,000+ unique users.  To learn more about why Aries Markets deployed on Aptos, visit ariesmarkets.xyz -- Ledger, the global leader in digital asset security, proudly sponsors Bell Curve! As Ledger celebrates 10 years of securing 20% of global crypto, it remains the top choice for securing your assets. Buy a LEDGER™ device now, and build confidently, knowing your BTC, ETH, SOL, and more are safe. Buy now on https://shop.ledger.com/?r=1da180a5de00. — Traders, AI enthusiasts, and degens—listen up! The game is changing, and DESK is leading the charge. Welcome to the next generation of perpetual trading—where cutting-edge technology meets AI-driven automation. Trade today at https://desk.exchange/?register-channel=BWpodcast and follow @TradeOnDESK on X! -- Morpho is a permissionless lending platform that allows anyone to earn yield and borrow assets on your terms. Its flexible, trustless infrastructure also empowers developers and businesses to build and tailor their own financial products. Whether you're an individual, fund, fintech, or institution, Morpho is for you. Try Morpho today: https://app.morpho.org/?network=mainnet&spdl=99nsk9 -- Missed DAS? Join us from June 24th-June 26th at Permissionless IV! Use Code BELL10 at checkout for 10% off! Tickets: https://blockworks.co/event/permissionless-iv -- Follow Zora: https://x.com/zora Follow Jacob: https://x.com/js_horne Follow Mike: https://x.com/MikeIppolito_ Subscribe on YouTube: https://bit.ly/3R1D1D9 Subscribe on Apple: https://apple.co/3pQTfmD Subscribe on Spotify: https://spoti.fi/3cpKZXH Get top market insights and the latest in crypto news. Subscribe to Blockworks Daily Newsletter: https://blockworks.co/newsletter/ Join the Bell Curve Telegram group: https://t.me/+nzyxAvQ0Xxc3YTEx -- Timestamps: (0:00) Introduction (1:04) Zora's History (5:13) Fractionalizing Assets (10:35) Ads (Aptos & Ledger) (11:07) The Royalty Debate (15:27) Capital Formation Around NFTs & Attention Markets (21:51) Ads (Aptos & Ledger) (22:58) Categories of Coins (29:47) Creator Monetization (36:17) What Does Zora Look Like Today? (40:14) Ads (Desk & Morpho) (41:09) Retail Speculation Over Time (44:41) Why Build on Top of Uniswap? (48:29) Future Features (52:45) A New Class of Market Makers (56:30) NFTs Are Not Dead -- Disclaimer: Nothing said on Bell Curve is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Mike, Jason, Michael, Vance and our guests may hold positions in the companies, funds, or projects discussed.

In this episode, we dive into the institutional adoption of crypto, stablecoin innovation, the implications of the GENIUS Act, and recent market drama involving Hyperliquid. We also explore the tough state of venture capital, and M&A activity in crypto. Thanks for tuning in! -- Resources Hyperliquid's Resolution: https://x.com/HyperliquidX/status/1905319339991204263 -- Namada is the shielded asset hub rewarding you to protect the multichain. Enabling data protection for any existing asset, app, or chain, Namada introduces shielded cross-chain actions and rewards for shielding your assets, which strengthens data protection guarantees for everyone. Namada is currently entering phase 3 of its mainnet launch — follow along on https://namada.net/ -- Marinade is the premier staking delegation platform on Solana, bringing billions in liquidity and security to the Solana network, and connecting SOL holders to the best staking rates. Since launching in 2021, Marinade has expanded their suite of products to provide solutions for both DeFi users and TradFi, including liquid and native staking, as well as direct enterprise integrations.  To learn more about Marinade, follow the link below: https://marinade.finance/?utm_source=blockworks&utm_medium=partnerships&utm_campaign=podcast -- Traders, AI enthusiasts, and degens—listen up! The game is changing, and DESK is leading the charge. Welcome to the next generation of perpetual trading—where cutting-edge technology meets AI-driven automation. Trade today at https://desk.exchange/?register-channel=BWpodcast and follow @TradeOnDESK on X! -- Morpho is a permissionless lending platform that allows anyone to earn yield and borrow assets on your terms. Its flexible, trustless infrastructure also empowers developers and businesses to build and tailor their own financial products. Whether you're an individual, fund, fintech, or institution, Morpho is for you. Try Morpho today: https://app.morpho.org/?network=mainnet&spdl=99nsk9 -- Missed DAS? Join us from June 24th-June 26th at Permissionless IV! Use Code BELL10 at checkout for 10% off! Tickets: https://blockworks.co/event/permissionless-iv -- Follow Mike: https://twitter.com/MikeIppolito_ Follow Michael: https://twitter.com/im_manderson Follow Vance: https://twitter.com/pythianism Subscribe on YouTube: https://bit.ly/3R1D1D9 Subscribe on Apple: https://apple.co/3pQTfmD Subscribe on Spotify: https://spoti.fi/3cpKZXH Get top market insights and the latest in crypto news. Subscribe to Blockworks Daily Newsletter: https://blockworks.co/newsletter/ Join the Bell Curve Telegram group: https://t.me/+nzyxAvQ0Xxc3YTEx -- Timestamps: (0:00) Introduction (2:10) Takeaways From DAS NYC (4:25) Getting Exposure to Stablecoin & RWA Growth (12:03) Ads (Namada & Marinade) (12:34) Institutional Stablecoin Announcements (21:09) The GENIUS Act (28:57) Ads (Namada & Marinade) (30:11) Hyperliquid Drama (46:34) Ads (Desk & Morpho) (47:29) Private Equity Lobbying to be Included in 401ks (52:11) M&A in Crypto and the State of Venture Capital (1:10:01) Justin Sun on the Cover of Forbes -- Disclaimer: Nothing said on Bell Curve is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Mike, Jason, Michael, Vance and our guests may hold positions in the companies, funds, or projects discussed, and our guests may hold positions in the companies, funds, or projects discussed.

Pour ce 850ème épisode du NFT Morning, John et Rem reçoivent (enfin!..) Aurélien Giraudon, CEO France de l'exchange SwissBorg. SwissBorg : une fintech crypto qui veut démocratiser la gestion de patrimoineCréée en 2017, SwissBorg compte aujourd'hui plus de 900 000 utilisateurs vérifiés, 1,4 milliard d'euros sous gestion, et plus de 200 collaborateurs. À mi-chemin entre startup et PME établie, la société revendique une mission claire : rendre la gestion de patrimoine accessible à tous, via les technologies Web3.Historiquement ancrée dans l'ADN suisse du "Wealth Management", SwissBorg veut casser les codes d'un univers longtemps réservé à une élite. Grâce à une approche user-friendly, elle tente de supprimer les barrières techniques et financières de la DeFi.Produits et services proposés par SwissBorgAurélien détaille plusieurs gammes de produits développés au sein de l'écosystème SwissBorg :* Marketplace de cryptomonnaies : permet d'acheter, vendre ou échanger n'importe quelle crypto de manière simple, avec un moteur de trading garantissant le meilleur prix.* Earn : système de rendement passif incluant stacking, restacking, liquid stacking et lending (notamment via Morpho).* Alpha : une offre destinée aux utilisateurs plus "tactiques" avec accès à des vaults, du farming d'airdrops ou des "early deals", à la manière de ce que font les VC.* Crypto Bundles : paniers thématiques d'actifs (meme coins, DeFi...), semblables à des index sectoriels.* Managed Portfolios (bientôt lancés) : une forme de gestion pilotée personnalisée en fonction du niveau de risque choisi par l'utilisateur, dans une logique de transparence et de simplification.SwissBorg mise aussi beaucoup sur l'éducation: À travers son blog, son académie ou les contenus intégrés dans l'app, l'objectif est de permettre aux utilisateurs de monter en compétence, sans pour autant les y obliger.La phrase à retenir« Notre mission chez SwissBorg, c'est de démocratiser la gestion de patrimoine en rendant la finance décentralisée accessible à tous, sans complexité mais avec transparence. »— Aurélien GiraudonLiens utiles pour les auditeurs* Site : www.swissborg.com* Compte Twitter de SwissBorg* Compte X d'Aurélien Giraudon * Profil LinkedIn d'Aurélien Giraudon* SwissBorg Academy : academy.swissborg.com* Replay vidéo de l'épisode ici This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.nftmorning.com

In this episode, we explore the transition from institutional resistance to adoption in crypto markets. David Mercer of LMAX Group discusses the convergence of TradFi and digital assets, the role of credit in unlocking institutional capital, and the need for clearer market structures. Thanks for tuning in! -- Aries Markets is the largest lending protocol on Aptos by TVL, and among the top 10 lending protocols across all blockchains! Since launch, Aries has expanded its product suite to become a fully integrated DeFi hub combining lending, borrowing, and more to its community of 738,000+ unique users.  To learn more about why Aries Markets deployed on Aptos, visit ariesmarkets.xyz -- Ledger, the global leader in digital asset security, proudly sponsors Bell Curve! As Ledger celebrates 10 years of securing 20% of global crypto, it remains the top choice for securing your assets. Buy a LEDGER™ device now, and build confidently, knowing your BTC, ETH, SOL, and more are safe. Buy now on https://shop.ledger.com/?r=1da180a5de00. -- Traders, AI enthusiasts, and degens—listen up! The game is changing, and DESK is leading the charge. Welcome to the next generation of perpetual trading—where cutting-edge technology meets AI-driven automation. Trade today at https://desk.exchange/?register-channel=BWpodcast and follow @TradeOnDESK on X! -- Morpho is a permissionless lending platform that allows anyone to earn yield and borrow assets on your terms. Its flexible, trustless infrastructure also empowers developers and businesses to build and tailor their own financial products. Whether you're an individual, fund, fintech, or institution, Morpho is for you. Try Morpho today: https://app.morpho.org/?network=mainnet&spdl=99nsk9 -- Missed DAS? Join us from June 24th-June 26th at Permissionless IV!  Tickets: https://blockworks.co/event/permissionless-iv -- Follow David: https://x.com/mercerdavid Follow Mike: https://x.com/MikeIppolito_ Subscribe on YouTube: https://bit.ly/3R1D1D9 Subscribe on Apple: https://apple.co/3pQTfmD Subscribe on Spotify: https://spoti.fi/3cpKZXH Get top market insights and the latest in crypto news. Subscribe to Blockworks Daily Newsletter: https://blockworks.co/newsletter/ Join the Bell Curve Telegram group: https://t.me/+nzyxAvQ0Xxc3YTEx -- Timestamps: (0:00) Introduction (1:24) Institutional Adoption of Crypto (4:13) Crypto vs TradFi Market Structures (8:22) Ads (Aptos & Ledger) (8:54) Regulation's Impact on Crypto's Path (12:01) Ads (Aptos & Ledger) (13:07) Rebuilding Crypto Credit (18:06) The Future of Crypto (21:08) Ads (Desk & Morpho) (22:03) Predictions on Institutional Adoption -- Disclaimer: Nothing said on Bell Curve is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Mike, Jason, Michael, Vance and our guests may hold positions in the companies, funds, or projects discussed.

Obol launches a 12.5m OBOL token incentives program. Coinbase introduces Verified Pools. Moonwell launches on OP Mainnet. And Spark announces the winners of its RWA competition. Read more: https://ethdaily.io/668

Ethereum developers introduce the Hoodi Ethereum testnet. Aave Labs proposes a RWA project. Compound Finance launches vaults on Morpho. And ZKsync cancels its Ignite program. Read more: https://ethdaily.io/665

Dr. John Sweetenham and Dr. James Foran discuss the evolving treatment landscape in acute myeloid leukemia, including new targeted therapies, advances in immunotherapy, and the current role for allogeneic transplantation. TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast. There has been steady progress in the therapies for acute myeloid leukemia (AML) in recent years, largely based on an increasing understanding of the molecular mechanisms which underlie the disease. On today's episode, we'll be discussing the evolving treatment landscape in AML. We'll explore risk group stratification, new targeted therapies, advances in immunotherapy for AML, and also a little about the current role for allogenic transplantation in this disease.  I'm delighted to welcome Dr. James Foran to this discussion. Dr. Foran is a professor of medicine and chair of the Myeloid Malignancies and Blood and Marrow Transplant Disease Group at the Mayo Clinic Comprehensive Cancer Center. He's based in Jacksonville, Florida.  Our full disclosures are available in the transcript of this episode.  James, it's great to have you join us on the podcast today, and thanks so much for being here. Dr. James Foran: I'm delighted and thank you for the invitation. Thank you very much. Dr. John Sweetenham: Sure, James, let's get right into it. So, our understanding of the molecular mechanisms underlying AML has resulted not only in new methods for risk stratification in this disease, which have added refinement to cytogenetics, but also has resulted in the development of many new targeted agents. Understanding that this is a complex area of investigation, and our time is somewhat limited, can you give us a high-level update on the current state of the art in terms of how risk factors are being used for treatment selection now? Dr. James Foran: Absolutely. I think in the past, you know, we had things broken down pretty simply into make a diagnosis based on morphology, do cytogenetics, break patients into the groups of those who were more likely to benefit from therapy – so-called favorable risk – those where the intensive therapies were less likely to work – so-called poor adverse risk, and then this large intermediate group that really had variable outcomes, some better, some worse. And for a long time, the progress was in just identifying new subtle cytogenetic risk groups. And then, late 1990s, we began to understand that FLT3 mutations or NRAS mutations may be more adverse than others that came along. In the first part of this millennium, in the, you know, 2000-2010 range, a lot of work was being done to understand better or worse risk factors with single genes. The ability to do multiplex PCR, and then more recently NGS platforms, have allowed us to really look at many genes and identify many mutations in patients. At the beginning that was used just to sort of refine – who did a little better, who did a little worse with intensive therapy – helped us decide who may benefit more from an allogeneic transplanter for whom that would not be necessary.  But the good news is that really, we're now starting to target those mutations. One of the first molecularly targeted treatments in leukemia was FLT3 mutations, where we knew they were adverse. Then along came targeted treatments. I was involved in some of those early studies looking at sunitinib, sorafenib, more recently midostaurin, now quizartinib, FDA approved, and gilteritinib in the relapse refractory setting.  So we're moving into a state where we're not just refining prognosis, we're identifying targets. You know, it's been slow progress, but definite incremental progress in terms of outcomes by looking for FLT3 mutations, then looking for IDH mutations, and more recently, mutations involving NPM1 or rearrangement of what we used to call the MLL gene, now the lysine methyltransferase 2A or KMT2A rearrangement, where we now have targets. And it's not just for refinement of prognosis, but now we're identifying therapeutic targets for patients and ways to even look for measurable residual disease which is impacting our care. Dr. John Sweetenham: That's great, James. And I'm going to expand on that theme just a little bit and perhaps ask you to elaborate a little bit more on how the introduction of these new therapies have specifically impacted frontline therapy. And a couple of ancillary questions maybe to go along with that: First of all, is ‘7+3' a standard therapy for anybody in 2025? And maybe secondly, you know, could you comment also maybe briefly on older patients with AML and how you think maybe the treatment landscape is changing for them compared with, say, 5 or 10 years ago? Dr. James Foran: I'll start with the therapy and then work my way back. So we've had ‘7+3' cytarabine daunorubicin or cytarabine anthracycline since 1976, and we're still using it as the backbone of our intensive therapy. There is still an important role for it, particularly in younger or fitter patients, and particularly for those with intermediate or favorable risk genetic groups or cytogenetic risk groups just because we achieve high rates of remission. Our 30-day induction mortality rates are lower now than they were 10 and 20 years ago. Our supportive care is better. And we still have a busy inpatient hospital service here at Mayo Florida and my colleagues in Rochester and Arizona as well giving intensive therapy. So that remains the backbone of curative therapy for younger adults. We are trying to be a little more discriminating about who we administer that to. We are trying to add targeted agents. We know from, now, two different randomized trials that the addition of a FLT3 inhibitor, either midostaurin or more recently quizartinib, has a survival advantage in patients with a FLT3 mutation, or for quizartinib, a FLT3/ITD mutation. And so yes, ‘7+3' remains important.  Off protocol for somebody who just comes in with acute leukemia in a 40-year-old or 30-year-old or even early 60s and fit, we would still be considering ‘7+3' therapy and then waiting for an expedited gene mutation panel and an expedited cytogenetics panel to come back to help us discriminate is that a patient for whom we should be giving a FLT3 inhibitor? I think there's a little more nuance about when we do a day 14 bone marrow, do they really matter as much anymore? I still do them. Some of my colleagues find them less important. But we're still giving intensive therapy. We're still giving high-dose ARA-C consolidation for younger patients who achieve complete remission.  In older adults, it's a different story. You know, it was only in the early part of the 2000s – 2004, 2007 range – where we really got buy-in from randomized studies that low-dose therapy was better than no therapy. There was a lot of nihilism before then about therapy for older adults, especially over age 75. We know that low-dose ARA-C is better than nothing. It looked like azacitidine was better than ARA-C or at least equivalent or slightly better. But with the advent of venetoclax it was a game changer. I ran a national randomized study of intensive therapy in AML. It was the last national randomized study of intensive therapy in older patients right before venetoclax got approved. And we were very excited about our results, and we thought we had some really interesting clinical results. And suddenly that's a little bit obsolete in patients over 70 and particularly over age 75 because of the high remission rates with azacytidine venetoclax or hypomethylating agents, so-called HMAs and venetoclax and the survival advantage. Now, it's not a home run for everybody. We quote 60% to 70% remission rates, but it's a little different based on your cytogenetics and your mutation profile. You have to continue on therapy so it's continuous treatment. It's not with curative intent, although there are some people with long-term remission in it. And the median survival went from 10 months to 15 months. So home run? No, but definitely improved remissions, meaningful for patients off transfusions and better survival. So right now it's hard to find an older adult who you wouldn't give azacitidine and venetoclax or something similar, decitabine, for instance, and venetoclax, unless somebody really was moribund or had very poor performance status or some reason not to. And so ‘7+3' is still relevant in younger adults. We're trying to get better results with ‘7+3' by adding targeted agents and azacitine and venetoclax in older adults.  I think the area of controversy, I guess there are two of them, is what to do in that overlap age between 60 and 75. Should people in that age still get intensive therapy, which we've used for years – the VIALE-A trial of aza-venetoclax was age 75 plus – or with cardiac comorbidities? And I think if you're 68 or 72, many of us are starting to bias towards aza-venetoclax as generally being better tolerated, generally being more outpatient, generally being slow and steady way to get a remission. And it doesn't stop you from going to transplant for somebody who might still be a candidate.  The other area of controversy is somebody under 60 who has adverse cytogenetics where we don't do very well with ‘7+3,' we still give it and we might do just as well with decitabine venetoclax. A lot of us feel that there's equipoise in the 60 to 75 group where we really can ask a question of a randomized study. Retrospective studies might suggest that intensive therapy is a little better, but there are now a couple of randomized studies happening saying, “Can we replace ‘7+3' in that intermediate age with aza-venetoclax?” And for younger adults similarly, we're looking to see how we apply that technology. Those are the areas where we're really trying to investigate what's optimal for patients and that's going to require randomized trials. Dr. John Sweetenham: Oh, that's great, thank you. And I'll just extend that question a little bit more, particularly with respect to the new targeted therapies. How much are they impacting the treatment of these patients in the relapse and refractory setting now? Dr. James Foran: Oh, they're definitely impacting it. When I trained and probably when you trained, AML was still a medical emergency. But that was the thing that you admitted to the hospital immediately, you started therapy immediately. The rule was always that's the one thing that brings the fellow and the consultant in at night to see that new patient on a Friday or Saturday. Now, we'll still admit a patient for monitoring, but we try not to start therapy for the first three or five or seven days if they're stable, until we get those genetics and those genomics back, because it helps us discriminate what therapy to pursue. And certainly, with FLT3 mutations, especially FLT3/ITD mutations, we're adding FLT3 inhibitors and we're seeing a survival advantage. Now, on the surface, that survival advantage is in the range of 7% or 10%. But if you then pursue an allogeneic transplant in first remission, you're taking disease where we used to see 30%, 40% long-term survival, maybe less, and you're pushing that to 60%, 70% in some studies. And so we're now taking a disease that– I don't want to get off topic and talk about Ph+ ALL. But that's a disease where we're actually a little excited. We have a target now, and it used to be something really adverse and now we can do a lot for it and a lot about it.  The other mutations, it's a little more subtle. Now, who knew until 2010 that a mutation in a sugar metabolism gene, in isocitrate dehydrogenase, or IDH was going to be so important, or even that it existed. We know that IDH1 and IDH2 mutations are still a minority of AML, certainly less than 10% to 15%, maybe overall. But we're able to target those with specific IDH1 and IDH2 inhibitors. We get single-agent responses. There are now two approved IDH1 inhibitors on the market. We don't yet have the randomized data that adding those to intensive therapy is better, but we're getting a very strong hint that it might be better in older adults who have an IDH mutation, maybe adding those is helpful and maybe adding those to low-intensity therapy is helpful. Those studies are ongoing, and we're also trying with low-intensity treatments to add these agents and get higher remission rates, deeper remissions, longer remissions. I think a lot of work has to be done to delineate the safety of that and the long-term efficacy. But we're getting hints it's better, so I think it is impacting.  The other area it's impacting is when you pick up adverse mutations and those have crept into our classification systems like an ASXL1 mutation or RUNX1 mutation for instance, or some of the secondary AML mutations like BCOR and others, where that's helping us discriminate intermediate-risk patients who we think aren't going to do as well and really helping us select a group who's more likely to get benefit from allogeneic transplant or for whom at least our cure rates without allo transplant are low. And so I think it's impacting a lot. Dr. John Sweetenham: Great. And I'm going to pick up now, if I may, on a couple of things that you've just mentioned and continue the theme of the relapsed and refractory setting. We've started to see some reports which have looked at the role of immune strategies for patients with AML, in particular CAR T or NK cells. Can you comment a little on this and let us know whether you think either these two strategies or other immune strategies are likely to have a significant role in AML in the future? Dr. James Foran: They are, but I think we're still a step behind finding the right target or the right way to do it. If you think of allogeneic transplantation as the definitive immune therapy, and we know for adverse AML we can improve survival rates and cure rates with an allotransplant, then we know inherently that immune therapy matters. And so how do we do what they've done in large cell lymphoma or in CD19 targeting for B cell malignancies? How do we bring that to acute myeloid leukemia? There have been a number of efforts. There have been at least 50 trials looking at different targets. CD33, CD123, CD7, others, CLL-1. So, there have been a number of different trials looking at how to bind a CAR T or a CAR T construct that can be active. And we have hints of efficacy. There was kind of a provocative paper in the New England Journal of Medicine a year ago in April of last year from a Chinese group that looked at a CD7-based CAR T and it was 10 patients, but they used CD7 positive acute leukemia, AML or ALL and had a CD7-targeted CAR T and they actually incorporated that with a haploidentical transplant and they had really high remission rates. People tolerated it quite well. It was provocative. It hasn't yet been reproduced on a larger scale, but the strong hints that the strategy is going to work.  Now, CD33 is a little tricky to have a CAR T when CD33 is expressed on normal hematopoietic cells. CD123 likewise. That's been something where there's, I think, still promise, but we've struggled to find the trials that make that work. Right now, there's a lot of interest in leveraging NK cells and looking, for a couple of reasons, but NK cells are attractive and NK cell markers might be attractive targets. NK cells might have similar degrees of immune efficacy. It's speculative, but they are likely to have less cytokine release syndrome and less neurotoxicity than you see with CAR T. And so it's kind of attractive to leverage that. We have had some ongoing trials looking at it with bispecifics and there certainly are trials looking at it with CAR NK-based strategies. One of the antigens that people looked at is the NK group 2D. NK group 2D or NKG2D is overexpressed in AML and its ligands overexpressed. And so that's a particular potential target. So, John, it's happening and we're looking for the hints of efficacy that could then drive a pivotal trial to get something approved.  One of the other areas is not restricting yourself just to a single antigen. For instance, there is a compound that's looking at a multi-tumor-associated antigen-specific T-cell therapy, looking at multiple antigens in AML that could be overexpressed. And there were some hints of activity and efficacy and actually a new trial looking at a so-called multi-tumor associated antigen-specific T cell therapy. So without getting into specific conflicts of interest or trials, I do think that's an exciting area and an evolving area, but still an investigational area. I'll stop there and say that we're excited about it. A lot of work's going there, but I'm not quite sure which direction the field's going to pivot to there. I think that's going to take us some time to sort out. Dr. John Sweetenham: Yeah, absolutely. But as you say, exciting area and I guess continue to watch this space for now.  So you've mentioned allogeneic stem cell transplants two or three times during this discussion. Recognizing that we don't have an imatinib for AML, which has kind of pushed transplant a long way further back in the treatment algorithm, can you comment a little on, you know, whether you think the role of stem cell transplantation is changing in AML or whether it remains pretty much as it was maybe 10 years ago? Dr. James Foran: By the way, I love that you use imatinib as an introduction because that was 6 TKIs ago, and it tells you the evolution in CML and you know, now we're looking at myristoyl pocket as a target, and so on. That's a great way to sort of show you the evolution of the field.  Allogeneic transplant, it remains a core treatment for AML, and I think we're getting much smarter and much better about learning how to use it. And I'm just going to introduce the topic of measurable residual disease to tell you about that. So I am a little bit of a believer. Part of my job is I support our allogeneic transplant program, although my focus is acute myeloid leukemia, and I've trained in transplant and done it for years and did a transplant fellowship and all that. I'm much more interested in finding people who don't need a transplant than people who do. So I'm sort of looking for where can we move away from it. But it still has a core role. I'll sidestep and tell you there was an MDS trial that looked at intermediate or high-risk MDS and the role of allogeneic transplant that shows that you about double your survival. It was a BMT CTN trial published several years ago that showed you about double your three-year survival if you can find a donor within three months and get to a transplant within six months. And so it just tells you the value of allotransplant and myeloid malignancy in general. In AML we continue to use it for adverse risk disease – TP53 is its own category, I can talk about that separately – but adverse risk AML otherwise, or for patients who don't achieve a really good remission. And I still teach our fellows that an allotransplant decreases your risk of relapse by about 50%. That's still true, but you have to have a group of patients who are at high enough risk of relapse to merit the non-relapse mortality and the chronic graft versus host disease that comes with it. Now, our outcomes with transplant are better because we're better at preventing graft versus host disease with the newer strategies such as post-transplant cyclophosphamide. There are now new FDA-approved drugs for acute and chronic graft versus host disease, ruxolitinib, belumosudil, axatilimab now. So we have better ways of treating it, but we still want to be discriminating about who should get it.  And it's not just a single-minded one-size-fits-all. We learned from the MORPHO study that was published in the JCO last year that if you have FLIT3-positive AML, FLIT3/IDT-positive AML, where we would have said from retrospective studies that your post-transplant survival is 60% give or take, as opposed to 15% or 20% without it, that we can discriminate who should or shouldn't get a transplant. Now that trial was a little bit nuanced because it did not meet its primary endpoint, but it had an embedded randomization based upon MRD status and they used a very sensitive test of measurable residual disease. They used a commercial assay by Invivoscribe that could look at the presence of a FLT3/ITD in the level of 10 to the minus 5th or 10 to the minus 6th. And if you were MRD-negative and you went through a transplant, you didn't seem to get an advantage versus not. That was of maintenance with gilteritinib, I'll just sort of put that on there. But it's telling us more about who should get a transplant and who shouldn't and who should get maintenance after transplant and who shouldn't.  A really compelling study a year ago from I don't know what to call the British group now, we used to call them the MRC and then the NCRI. I'm not quite sure what to call their studies at the moment. But Dr. Jad Othman did a retrospective study a year ago that looked at patients who had NPM1 mutation, the most common mutation AML, and looked to see if you were MRD positive or MRD negative, what the impact of a transplant was. And if you're MRD negative there was not an advantage of a transplant, whereas if you're MRD positive there was. And when they stratified that by having a FLT3 mutation that cracked. If you had a FLT3 mutation at diagnosis but your NPM1 was negative in remission, it was hard to show an advantage of a transplant. So I think we're getting much more discriminating about who should or should not get a transplant by MRD testing for NPM1 and that includes the patients who have a concomitant FLT3 mutation. And we're really trying to learn more and more. Do we really need to be doing transplants in those who are MRD-negative? If you have adverse risk genetics and you're MRD-negative, I'll really need good data to tell me not to do a transplant, but I suspect bit by bit, we'll get that data. And we're looking to see if that's really the case there, too. So measurable residual disease testing is helping us discriminate, but there is still a core role of allogeneic transplant. And to reassure you, compared to, I think your allotransplant days were some time ago if I'm right. Dr. John Sweetenham: Yes. Dr. James Foran: Yeah. Well, compared to when you were doing transplants, they're better now and better for patients now. And we get people through graft versus host disease better, and we prevent it better. Dr. John Sweetenham: That's a great answer, James. Thanks for that. It really does help to put it in context, and I think it also leads us on very nicely into what's going to be my final question for you today and perhaps the trickiest, in a way. I think that everything you've told us today really emphasizes the fact that the complexity of AML treatment has increased, primarily because of an improved understanding of the molecular landscape of the disease. And it's a complicated area now. So do you have any thoughts on what type of clinical environment patients with AML should be evaluated and treated in in 2025? Dr. James Foran: Yeah, I want to give you a kind of a cautious answer to that because, you know, I'm a leukemia doctor. I work at a leukemia center and it's what we focus on. And we really pride ourselves on our outcomes and our diagnostics and our clinical trials and so on. I am very aware that the very best oncologists in America work in private practice and work in community practice or in networks, not necessarily at an academic site. And I also know they have a much harder job than I have. They have to know lung cancer, which is molecularly as complicated now as leukemia, and they have to know about breast cancer and things that I don't even know how to spell anymore. So it's not a question of competence or knowledge. It's a question of infrastructure. I'll also put a little caveat saying that I have been taught by Rich Stone at Dana-Farber, where I did a fellowship a long time ago, and believe Rich is right, that I see different patients than the community oncologists see with AML, they're seeing different people. But with that caveat, I think the first thing is you really want to make sure you've got access to excellence, specialized hematopathology, that you can get expedited cytogenetics and NGS testing results back. There was a new drug, approved just a few months ago, actually, for relapsed AML with a KMT2A rearrangement, revumenib. We didn't talk about the menin inhibitors. I'll mention them in just a second. That's a huge area of expansion and growth for us. But they're not found on NGS platforms. And normal cytogenetics might miss a KMT2A-rearrangement. And we're actually going back to FISH panels, believe it or not, on AML, to try to identify who has a KMT2A-rearrangement. And so you really want to make sure you can access the diagnostic platforms for that.  I think the National Referral Labs do an excellent job. Not always a really fast job, but an excellent job. At my institution, I get NGS results back within three days or four days. We just have an expedited platform. Not everybody has that. So that's the key, is you have to be able to make the diagnosis, trust the pathologist, get expedited results. And then it's the question of trying to access the targeted medications because a lot of them are not carried in hospital on formulary or take time to go through an insurance approval process. So that's its own little headache, getting venetoclax, getting gilteritinib, getting an IDH1 inhibitor in first line, if that's what you're going for. And so I think that requires some infrastructure. We have case managers and nurses who really expedite that and help us with it, but that's a lot of work. The other piece of the puzzle is that we're still with AML in the first month and maybe even the second month. We make everybody worse before we make them better. And you have to have really good blood bank support. I can give an outpatient platelet transfusion or red cell transfusion seven days a week. We're just built for that. That's harder to do if you're in a community hospital and you have to be collaborating with a local blood bank. And that's not always dead easy for somebody in practice. So with those caveats, I do find that my colleagues in community practice do a really good job making the diagnosis, starting people on therapy, asking for help. I think the real thing is to be able to have a regional leukemia center that you can collaborate with, connect with, text, call to make sure that you're finding the right patients who need the next level of diagnostics, clinical trial, transplant consults, to really get the best results.  There was some data at ASH a couple of years ago that looked at – the American Society of Hematology and ASCOs had similar reports – that looked at how do we do in academic centers versus community practice for keeping people on therapy. And on average, people were more likely to get six cycles of therapy instead of three cycles of therapy with azacitidine venetoclax at an academic center. Now, maybe it's different patients and maybe they had different cytogenetics and so on, but I think you have to be patient, I think you have to collaborate. But you can treat those patients in the community as long as you've got the infrastructure in place. And we've learned with virtual medicine, with Zoom and other platforms that we can deliver virtual care more effectively with the pandemic and beyond. So I think we're trying to offer virtual consults or virtual support for patients so they can stay in their home, stay in their community, stay with their oncologists, but still get access to excellent diagnostics and supportive care and transplant consults, and so on. I hope that's a reasonable answer to that question. It's a bit of a nuanced answer, which is, I think there's an important role of a leukemia center, and I think there's a really fundamental role of keeping somebody in the community they live in, and how we collaborate is the key to that. And we've spent a lot of time and effort working with the oncologists in our community to try to accomplish that.  John, I want to say two other things. I didn't mention in the molecular platforms that NPM1 mutations, we can now target those on clinical trials with menin inhibitors. We know that NPM1 signals through the Hoxa9/Meis1 pathway. We know that similar pathways are important in KMT2A rearrangements. We know that there are some other rare leukemias like those with NUP98 rearrangement. We can target those with menin inhibitors. The first menin inhibitor, revuminib, was approved by the FDA for KMT2A. We have others going to the FDA later this year for NPM1. There are now pivotal trials and advanced expanded phase 1/2 studies that are showing 30% response rates. And we're looking to see can we add those into the first-line therapy. So, we're finding more targets.  I'll say one last thing about molecular medicine. I know I'm a little off topic here, but I always told patients that getting AML was kind of like being struck by lightning. It's not something you did. Now, obviously, there are risk factors for AML, smoking or obesity or certain farm environments, or radioactive exposures and so on. But bit by bit, we're starting to learn about who's predisposed to AML genetically. We've identified really just in the last five or eight years that DDX41 mutations can be germline half the time. And you always think germline mutations are going to cause AML in a younger patient, but the median age is 60 to 70 just like other AMLs. They actually might do pretty well once they get AML. We've reported that in several papers. And so we're trying to understand who that has a RUNX1 mutation needs germline testing, who with a DDX41 needs germline testing. And we're trying to actually come up with a cleaner pathway for germline testing in patients to really understand predisposition, to help with donor selection, to help with family counseling. So I think those are other areas where a leukemia center can contribute for somebody in who's community practice to understand genomic or genetic complexity in these patients. And we're starting to develop the databases that support that. Dr. John Sweetenham: Yeah, great. Thanks, James. I loved your answer about the clinical environment too. And I know from a patient-centric perspective that I know that patients would certainly appreciate the fact that we're in a situation now where the folks taking care of them will make every effort to keep them close to home if they possibly can.  I want to thank you, James, for an incredible review of a very complex subject and I think you did a great job. I think we all will have learned a lot. And thanks again for being willing to share your insights with us today on the ASCO Daily News Podcast. Dr. James Foran: John, it's my pleasure. And as you know, I'll do anything for a latte, so no problem at all. Dr. John Sweetenham: Okay. I owe you one, so thank you for that.  And thank you to our listeners for your time today. You'll find links to the studies we've discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:  Dr. John Sweetenham  Dr. James Foran Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook  ASCO on LinkedIn  Disclosures:    Dr. John Sweetenham:    No relationships to disclose Dr. James Foran: Stock and Other Ownership Interests: Aurinia Pharmaceuticals Consulting or Advisory Role: Peerview, CTI BioPharma Corp, Remix Therapeutics, Cardinal Health, Medscape, Syndax, Autolus Therapeutics Research Funding (Inst.): Chordia Therapeutics, Abbvie, Actinium Pharmaceuticals, Kura Oncology, Sellas Life Sciences, Novartis, Roivant, Celgene/Bristol-Myers Squibb, Astellas Pharma, SERVIER Travel, Accommodations, Expenses: Peerview

Joining us this week is Alex Thorn to break down why crypto markets are taking a hit. Major hacks, bearish macro signals, and fresh tariffs from the U.S. all played a role. But it's not all bad news: the SEC is backing off from lawsuits against Coinbase, OpenSea, and Uniswap, signaling a potential shift in regulatory pressure. Plus, Bybit suffered the biggest crypto hack ever, losing $1.5B—how did it happen, and who's behind it? Follow Alex: https://x.com/intangiblecoins ------

Will Robinson, VP of Engineering at Coinbase, explores the company's expanding role in decentralized finance (DeFi), highlighting the launch of Bitcoin-backed USDC loans through Morpho and Coinbase's broader efforts to integrate DeFi solutions. He explains how Coinbase is working to connect centralized finance (CeFi) with DeFi by incorporating decentralized protocols while prioritizing security and regulatory compliance. Robinson also discusses the introduction of cbBTC as an alternative to WBTC, the company's approach to multi-chain development, and its plans for further DeFi integrations. Additionally, he addresses ongoing debates about Ethereum Layer 2 networks and their impact on the main chain, emphasizing the importance of improved cross-chain interoperability. He also provides insights into Coinbase's asset listing process, the role of meme coins in the crypto ecosystem, and the company's broader mission to support a more open and accessible financial system.Chapters00:00 - Intro: Will Robinson, VP of Engineering at Coinbase00:45 - Coinbase's expanding role in DeFi01:16 - Bitcoin-backed USDC loans powered by Morpho02:34 - How Coinbase enables BTC holders to access liquidity05:15 - Risks involved in Bitcoin-backed loans08:58 - Liquidation risks and loan-to-value ratios11:13 - Early demand and adoption of the product13:15 - cbBTC vs. WBTC: Why Coinbase launched its own Bitcoin wrapper18:47 - How cbBTC is issued and traded21:36 - Coinbase's approach to self-custody and wallets24:07 - The role of Coinbase Wallet in bridging CeFi and DeFi27:31 - Coinbase's long-term DeFi strategy and future integrations29:50 - Will DeFi become a mainstream part of traditional finance?33:51 - Coinbase's evolution from exchange to financial institution34:34 - The rise of Base: How Coinbase grew its Layer 238:28 - Are Layer 2s parasitic to Ethereum?49:08 - The role of meme coins in crypto and Coinbase's listing process54:20 - The future of on-chain finance and economic freedom✨ Check out our new website ✨https://thedefiant.io/

In this episode of the Crypto 101 podcast, hosts Bryce Paul and Brendan Viehman engage with Merlin Egalite, head of integrations at Morpho, discussing the evolving landscape of cryptocurrency, particularly focusing on Bitcoin loans and the integration of decentralized finance (DeFi) with traditional finance. Merlin shares his journey into the blockchain space, the innovative features of Morpho, and the potential future of DeFi, especially with the intersection of artificial intelligence. The conversation highlights the growing adoption of crypto products and the implications for users and the financial industry as a whole.Chapters00:00 Introduction to the Crypto Landscape01:57 Merlin Egalite's Journey to Morpho08:26 Innovations in Bitcoin Loans15:30 Understanding Loan Utilization and Risks20:00 Morpho's Growth and Market Potential27:11 The Role of Morpho Token in the Ecosystem30:15 Future of DeFi and AI IntegrationCheck out CoinFlip and use my code CRYPTO101 for a great deal: https://coinflip.techGet immediate access to my entire crypto portfolio for just $1.00 today! https://www.cryptorevolution.com/cryptnation-directGet your FREE copy of "Crypto Revolution" and start making big profits from buying, selling, and trading cryptocurrency today: https://www.cryptorevolution.com/freeMERCH STOREhttps://cryptorevolutionmerch.com/Subscribe to YouTube for Exclusive Content:https://www.youtube.com/@crypto101podcastFollow us on social media for leading-edge crypto updates and trade alerts:https://twitter.com/Crypto101Podhttps://instagram.com/crypto_101Guest Linkshttps://x.com/merlinegalite?lang=enhttps://x.com/MorphoLabs*This is NOT financial, tax, or legal advice*Boardwalk Flock LLC. All Rights Reserved 2025. ▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬Fog by DIZARO https://soundcloud.com/dizarofrCreative Commons — Attribution-NoDerivs 3.0 Unported — CC BY-ND 3.0 Free Download / Stream: http://bit.ly/Fog-DIZAROMusic promoted by Audio Library https://youtu.be/lAfbjt_rmE8▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬Our Sponsors:* Check out CoinFlip and use my code CRYPTO101 for a great deal: https://coinflip.tech* Check out NPR: https://npr.orgAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

This week's Weekly Rollup covers Trump's clash with the Fed over interest rates and the surprising crypto moves from Trump Media. Gauntlet's Tarun Chitra joins us to unpack the latest developments—from OpenSea's upcoming airdrop to Arbitrum's permissionless fault proofs—while we debate whether airdrops are truly over. We also dig into Vitalik's “communist” joke and Dave Portnoy's memecoin mania. Tune in for all the drama and alpha happening in the second week of February! ------

In this episode, we speak with Smokey the Bera, co-founder of Berachain, about the project's newly launched mainnet and its innovative Proof of Liquidity model. The discussion unpacks Berachain's unique three-way relationship between its app layer, validators, and a nontransferable governance token that reimagines traditional proof of stake systems. Smokey explores both the potential benefits and the challenges of this economic experiment as it seeks to reshape blockchain economics. We also spotlight our sponsor Morpho, whose cutting-edge integration of DeFi with traditional finance is driving new opportunities in the market. ------

Morpho expands the Morpho Stack to multiple chains. L2Beat refines Stage 1 rollup requirements. And Fileverse releases updates for dDocs. Read more: https://ethdaily.io/636

In this episode, our Blockworks Research analysts discuss the launch of Trump's memecoin, Solana's boom in activity, and the SIMD 228 proposal. They also dive into the Base ecosystem, ETH blobs, and the Coinbase x Morpho partnership. Thanks for tuning in! As always, remember this podcast is for informational purposes only, and any views expressed by anyone on the show are solely their opinions, not financial advice. -- Resources SIMD 228: Reducing SOL's Inflation: https://app.blockworksresearch.com/flashnotes/simd-228-reducing-sol-s-inflation Base DEX Volume: https://x.com/smyyguy/status/1881417994322214985 Coinbase x Morpho: https://x.com/MorphoLabs/status/1879903267146309805 -- SKALE is the next evolution in Layer 1 blockchains with a gas-free invisible user experience, instant finality, high speed, and robust security. SKALE is built different as it allows for limitless scalability and has already saved its 45 Million users over $9 Billion in gas fees. SKALE is high-performance and cost-effective, making it ideal for compute-intensive applications like AI, gaming, and consumer-facing dApps. Learn more at skale.space and stay up to date with the gas-free invisible blockchain on X at @skalenetwork -- Ledger, the global leader in digital asset security, proudly sponsors 0xResearch! As Ledger celebrates 10 years of securing 20% of global crypto, it remains the top choice for securing your assets. Buy a LEDGER™ device now and build confidently, knowing your precious tokens are safe. Buy now on https://shop.ledger.com/?r=1da180a5de00. -- Join us at DAS NYC 2025!  Use code 0x10 for a 10% discount: https://blockworks.co/event/digital-asset-summit-2025-new-york -- Follow Carlos: https://x.com/0xcarlosg Follow Dan: https://x.com/smyyguy Follow Marc: https://x.com/marcarjoon Follow Danny: https://x.com/defi_kay_ Follow Blockworks Research: https://x.com/blockworksres Subscribe on YouTube: https://bit.ly/3foDS38 Subscribe on Apple: https://apple.co/3SNhUEt Subscribe on Spotify: https://spoti.fi/3NlP1hA Get top market insights and the latest in crypto news. Subscribe to Blockworks Daily Newsletter: https://blockworks.co/newsletter/ Join the 0xResearch Telegram group: https://t.me/+z0H6y2bS-dllODVh -- Timestamps: (0:00) Introduction (1:39) Trump's Memecoin Launch (11:58) Ads (SKALE, Ledger) (12:38) Solana's Immense Rise in Activity (28:41) Solana's Liveness Struggles (35:56) Prioritizing Token Holders vs Stakers (42:07) Understanding SIMD 228 (47:56) Ads (SKALE, Ledger) (49:12) The Base Ecosystem (57:54) Where Are ETH Blobs Going? (1:07:01) Coinbase X Morpho Partnership (1:18:51) Closing Thoughts -- Check out Blockworks Research today! Research, data, governance, tokenomics, and models – now, all in one place Blockworks Research: https://www.blockworksresearch.com/ Free Daily Newsletter: https://blockworks.co/newsletter -- Disclaimer: Nothing said on 0xResearch is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Boccaccio, Dan, and our guests may hold positions in the companies, funds, or projects discussed.

President Trump issues an executive order on digital assets. Liquity V2 goes live on mainnet. Morpho Labs introduces Bundler3. And Circle launches a USDC Paymaster. Read more: https://ethdaily.io/632

We unpack the explosive market moves as Bitcoin hits a new all-time high of $110K and Solana reaches $293 as crypto welcomes President Trump. TRUMP Coin's debut contributed to the market frenzy, while COIN50 posted an impressive 8.74% weekly gain, signaling strong momentum as new users flood into the crypto space.We provide a financing overview, highlighting DeFi lending growth on Solana, funding rate fluctuations, and weekend liquidations. Onchain activity breaks records with DEX volumes at all-time highs, despite some network degradation and Ethereum's leadership reshuffle. The team also runs through Coinbase's partnership with Morpho in the U.S. that now allows clients to take USD loans using DeFi protocols secured by their Bitcoin, marking a significant innovation in crypto-backed lending.ETF inflows soar with $2B in Bitcoin ETFs and $213M in Ethereum ETFs, alongside MicroStrategy's bold addition of $1.1B in BTC.On the macro front, we preview the upcoming Fed meeting and discuss its implications for crypto markets.Topics Covered:Market Highlights: BTC & SOL ATHs, Trump Coin launch, and COIN50's strong performance.Financing Trends: DeFi lending on Solana and funding rate insights.On-Chain Activity: Record DEX volumes, network challenges, and Ethereum's leadership changes.ETF and Corporate Moves: Large inflows and MicroStrategy's BTC holdings.Macro Preview: Key updates ahead of the Fed meeting.Links:Coinbase Research2025 Crypto OutlookLiquid Staking WebinarHost: Ben Floyd, Head of Execution ServicesPanelists: David Duong, Head of Institutional Research David Han, Research AnalystZaid Khan, Head of EMEA Financing 

In today's episode Morpho CEO Paul Frambot breaks down their partnership with Coinbase that enables Bitcoin-backed loans through DeFi infrastructure. The conversation explores how Morpho's modular architecture allows seamless integration for major institutions while maintaining transparency and risk controls. Paul discusses Morpho's evolution from focusing purely on institutional clients to balancing both retail and B2B strategies. To close Mike and Paul discuss their thoughts on regulation, memecoins, and the challenging balance between innovation and user protection in DeFi. - - Follow Paul: https://x.com/PaulFrambot Follow Mike: https://x.com/MikeIppolito_ Follow Expansion: https://x.com/ExpansionPod_ Subscribe on YouTube: https://www.youtube.com/@ExpansionPod Subscribe on Apple: http://apple.co/4bGKYYM Subscribe on Spotify: http://spoti.fi/3Vaubq1 Get top market insights and the latest in crypto news. Subscribe to Blockworks Daily Newsletter: https://blockworks.co/newsletter/ -- Timestamps: (00:00) Introduction (02:08) US Crypto Strategic Reserve (15:26) Tether's USDT Zero (23:28) USDC vs USDT (30:22) Ink vs Base Interop (34:08) App Chains vs Gen Purpose (38:42) Do Bitcoiners Want L2s? (50:12) Solana's Market Share (54:29) Coinbase USDC Loans on BTC (59:58) Unwarranted Bankless Fire (01:03:57) Crypto's Funding Mechanisms - - Disclaimer Expansion was kickstarted by a grant from the Celestia Foundation. Nothing said on Expansion is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Rex, Jon, and our guests may hold positions in the companies, funds, or projects discussed.

Tarun Gupta is the Founder at Coinshift. In this episode, we review a new yield-bearing stablecoin called csUSDL, designed to be the ultimate treasury reserve asset. With hundreds of billions sitting idle in stablecoins, Coinshift hopes to provide DAOs, onchain liquid funds, and even retail DeFi users with permissionless access to a more scalable yield-bearing stablecoin backed by RWAs. This is a great episode to also understand why builders work with Morpho, and why they see such a huge opportunity to meet the demand for yield-bearing stablecoins onchain. ------

This week's episode dives into the evolving landscape of crypto as we approach a new administration. We discuss Donald Trump's upcoming presidency and what it could mean for markets, analyze the recent market turmoil despite positive economic indicators, and break down the SEC's case against Elon Musk. We also explore Sony's controversial L2 launch and Tether's move to El Salvador. Finally, some an exciting new privacy tool teams up with Coinbase.  ------

Morpho and Ondo are exploding, and there's speculation about Coinbase's secret alliance with Trump shaking up the market! Get the inside scoop on these top altcoins and what this potential partnership means for crypto's future. Listen now for the latest crypto news! ➡️  Join Telegram Trade with Josh - https://t.me/+vS5uDtG57XpjNDA1

Coinbase supports Bitcoin-backed USDC loans. Aevo transitions from Celestia to EigenDA. Tradable brings RWAs to ZKsync Era. And Base shares its 2025 mission. Read more: https://ethdaily.io/627

This week, we explore Bitcoin's increasing institutional adoption, with MicroStrategy expanding its holdings and other companies considering BTC for their balance sheets. We analyze ETF flows over the past two weeks and provide a Q1 market outlook, focusing on key drivers and emerging trends. In the macro segment, we examine pro-crypto regulatory appointments, potential legislation from a crypto-friendly Congress, and the Fed's rate outlook for H1. We also discuss the implications of economic data volatility and what Canada's potential new leadership could mean for Bitcoin. Additionally, we highlight global moves toward Bitcoin as a strategic reserve.Onchain, we delve into the growth of protocols like Morpho, Babylon, and Pendle, alongside AI agents gaining traction, with Eliza ai16z's GitHub surpassing Google Gemini in stars. We also explore the significance of high DEX volumes and Backpack's acquisition of FTX's EU operations, shedding light on its impact on European derivatives markets.Topics Covered:Market: Institutional BTC adoption, ETF flows, and Q1 market outlook.Macro: Pro-crypto regulatory changes, potential legislation, Fed rate trajectory, and global BTC reserves.On-Chain: Protocol growth, AI agent innovation, and European market developments through Backpack's FTX acquisition.Host: Ben Floyd, Head of Execution ServicesPanelists: David Duong, Head of Institutional Research David Han, Research Analyst Georg Toropov, CES Sales Trader

ZKsync Ignite liquidity incentives go live on ZKsync Era. Superstate launches USCC on Morpho. Optimism releases its 2024 recap. And EigenLayer announces the Eliza AI Agent Hacker House. Read more: https://ethdaily.io/619

Evgeny Gokhberg is the Founder and Managing Partner at Re7 Capital. In this episode, we explore how institutional strategies are shaping the future of DeFi. From managing risk and optimizing yields to navigating liquid tokens, venture investments, and even memecoins, we cover it all. We also dive into Re7's involvement with modular protocols like Morpho and Euler, shedding light on the evolving role of curated vaults. Whether you're curious about crypto venture trends or wondering if we're on the cusp of a bull run, this episode has something for every DeFi enthusiast. ------

Mamad Sylla, fondateur du compte Instagram "The Impact Story", a accumulé plus de 330 000 followers et a lancé un podcast dédié aux solutions écologiques. Dans cet épisode, nous parlons de comment Mamad pense que dénoncer les problèmes n'est pas la bonne solution, mais qu'il faut plutôt mettre en avant les solutions concrètes que des citoyens, des entrepreneurs et des activistes proposent à travers le monde.J'ai questionné Mamad sur la manière dont il est passé d'une carrière en finance à un engagement profond dans la transition écologique et sociale, notamment en rejoignant un fonds d'investissement à impact. Nous avons discuté de la responsabilité des banques dans le financement des énergies fossiles et de l'importance de réorienter les récits autour de l'écologie, en adoptant une approche plus positive et inspirante.Dans cet épisode, nous parlons de pourquoi il est essentiel d'arrêter de parler de problèmes en permanence et de mettre en lumière ceux qui trouvent des solutions. Mamad explique également comment son expérience personnelle, en grandissant entre le Mali, la banlieue parisienne et Paris, l'a poussé à s'intéresser aux inégalités sociales et, plus tard, à l'écologie.J'ai aussi échangé avec lui sur les transformations positives que nous vivons, notamment à travers des exemples concrets de projets comme Morpho, qui utilise des drones pour reforester massivement, ou encore des solutions sociales comme Colette, une initiative qui lutte contre la précarité des étudiants et l'isolement des personnes âgées.Dans cet épisode, nous explorons également comment changer les narratifs sur l'écologie peut motiver plus de personnes à agir, non pas par culpabilité, mais par envie d'un futur plus heureux et harmonieux.Je vous laisse découvrir cette discussion inspirante avec Mamad. Bonne écoute !Les questions que l'on se pose : Peux-tu nous raconter l'histoire de ton compte Instagram "The Impact Story" et pourquoi tu l'as lancé ?Qu'est-ce qui t'a sensibilisé à l'écologie et à la transition écologique ?Pourquoi penses-tu qu'il est essentiel de parler des solutions plutôt que des problèmes liés à l'écologie ?Quelles sont, selon toi, les erreurs dans la manière dont l'écologie est souvent présentée ?Quel est le rôle de la finance dans la lutte contre le changement climatique ?Quelles sont les solutions concrètes que tu partages sur "The Impact Story" ?Qu'est-ce que tu dirais aux personnes qui ne veulent plus entendre parler d'écologie ?Penses-tu qu'il est important de réorienter nos récits sur l'avenir pour qu'ils soient plus optimistes ?Quels sont les projets qui t'ont le plus marqué en matière d'impact écologique et social ?Le timelaps : 00:00 – Introduction de Mamad et son compte Instagram "The Impact Story".02:50 – Mamad raconte comment il a lancé son compte pour partager des solutions écologiques.05:00 – Sensibilisation de Mamad à l'écologie et transition dans la finance à impact.07:14 – Pourquoi les gens se lassent des discours écologiques et comment changer cela.09:30 – Importance de rendre l'écologie attrayante et motivante par des récits positifs.12:00 – Projets concrets de reforestation avec drones et solutions technologiques.16:30 – Comment chacun peut agir à son échelle pour un impact écologique collectif.21:25 – Le rôle des récits dans la transformation sociétale.29:23 – L'importance de la fiction pour réimaginer un futur positif.41:15 – Changements rapides dans les comportements écologiques grâce à l'influence et aux nouveaux récits. Suggestion d'autres épisodes à écouter : #170 Ecologie: dépasser les fausses bonnes idées avec Hélène de Vestele (https://audmns.com/NsiNltm) #132 Ecologie, les entreprises peuvent-elles contribuer positivement? Avec Fabrice Bonnifet (https://audmns.com/UrCaRQm) [HORS SERIE] Ecologie et mode de vie: comment réagir sans tout sacrifier? (https://audmns.com/iDvwTfO)

Paul Frambot, co-founder and CEO of Morpho Labs, explains how Morpho is a decentralized and permissionless lending protocol that allows users to create customized lending and borrowing pools. Unlike traditional DeFi platforms like Aave, Morpho externalizes risk management, giving users control over their risk exposure and liquidity. Frambot shares how Morpho started as a rate-optimizing solution and evolved into Morpho Blue, a more scalable protocol with over $1 billion in deposits. He discusses the advantages of building in Europe, Morpho's vision to make financial infrastructure a public good, and how fintech partnerships could drive future DeFi adoption. We also touch on Morpho's upcoming token launch and its long-term strategy to compete with other major DeFi protocols. 0:00 - Intro to Paul Frambot 0:30 - What is Morpho and How it Differs from Competitors 2:00 - Paul's Background and Entry into DeFi 3:30 - Early Development of Morpho Optimizer 5:00 - Transition to Morpho Blue and Permissionless Lending 8:00 - Managing Risk, Liquidity, and Customization 11:00 - Real-World Assets and New Use Cases in DeFi 14:00 - Challenges and Advantages of Building in Europe 18:00 - Morpho's Long-Term Vision: Financial Infrastructure as a Public Good 23:00 - Future of DeFi: Fintech Integration and Token Launch 28:00 - Competition with Aave and Growth Strategy 33:00 - The Role of Fintech in Scaling DeFi 38:00 - Long-Term Vision for DeFi and Fintech 43:00 - Morpho's Upcoming Tokenomics and Governance 48:00 - Future Trends and Adoption in DeFi 52:00 - Closing Thoughts and Paul's Outlook on DeFi This episode was sponsored by: NEAR: https://redactedbangkok.ai/?utm_source=thedefiant&utm_medium=referral&utm_campaign=defiant&utm_content=newsletter Stellar: https://stellar.org/soroban?utm_source=defiant&utm_medium=cpc&utm_campaign=defiant_podcast ✨ Check out our new website ✨ https://thedefiant.io/

Tune in to this episode of the Security Token Show where this week Herwig Konings and Nico Pantelis cover the industry leading headlines and market movements, including Maple, Provenance, REtokens, NAV Lend and the Last RWA Industry August News    This week Jason Barraza had a chance to host 3 interviews for you: Anthony Moro from ProvLabs and Alfred Macdaniel from Nav Lend on their fund issuance, trading, admin, and NAV lending Solution.   Sid Powell covering Maple's new $365M TVL milestone, Syrup protocol, and September plans.   Tyler Vinson from REtokens talks about tokenizing a church, updates on other offerings, and an exclusive: REtokens plans on launching an alternative trading system (ATS) in March 2025!   Company of the Week - Herwig: Morpho Labs Company of the Week - Kyle: Centrifuge    = Stay in touch via our Social Media = Kyle: https://www.linkedin.com/in/kylesonlin/  Herwig: https://www.linkedin.com/in/herwigkonings/ Nico: https://www.linkedin.com/in/nicopantelis/  Jason: https://www.linkedin.com/in/jasonbarraza/  Opinion articles, interviews, and more: https://medium.com/security-token-group  Find the video edition of this episode on our Youtube Channel: https://www.youtube.com/@stmtvofficial    The Market Movements Sky Launches New Stablecoin, Governance Token: https://www.coindesk.com/business/2024/08/27/makerdao-is-now-sky-as-7b-crypto-lender-rolls-out-new-stablecoin-governance-token/   Centrifuge Launches Lending Market with Morpho and Coinbase: https://www.coindesk.com/business/2024/08/27/tokenization-pioneer-centrifuge-unveils-lending-market-with-morpho-coinbase/   PYUSD Crosses $1B Market Cap, Expanded to Solana: https://www.coindesk.com/markets/2024/08/26/paypals-stablecoin-hits-1b-market-cap-as-incentives-boost-activity-on-solana/   Sony Announces ETH L2 Soneium: https://x.com/soneium/status/1828606372574859575 The Token Debrief French Financial Services Firm Natixis Pfandbriefbank Launching €100M Digital Bond on SWIAT Blockchain: https://www.linkedin.com/posts/swiat_blockchaintechnology-swiat-digitalassets-activity-7234481385753706496-JOLF   AAA-Rated $300M Digital Note by Asian Infrastructure Investment Bank (AIIB) via Euroclear Was Successful: https://www.marketsmedia.com/asian-infrastructure-investment-bank-issues-its-first-digitally-native-note/   German-based MyHouse with Tokenforge and Nyala Launches Tokenized Real Estate Platform Featuring Deals from DEGAG: https://de.cointelegraph.com/press-releases/myhouse-launches-the-first-tokenized-real-estate-investment-platform-for-degag   Tequila RWA from Blocksquare Announced as Industry First: https://www.thestreet.com/crypto/newsroom/blocksquare-partners-for-first-tokenization-of-a-tequila-distillery   A $5 Million Art Collection Gets Tokenized on Boson by Superchief Gallery: https://thedefiant.io/news/nfts-and-web3/boson-protocol-and-superchief-gallery-tokenize-usd5-1-million-art-collection   Redwood Securitizes 21st Vehicle on LiquidFi, Tops $8.5 Billion Total: https://www.linkedin.com/posts/rwthorizons_rwthorizons-rwt-securitizations-activity-7234953116612190208-4o5K   DCJPY Announces Production Launch in Japan: https://www.ledgerinsights.com/japanese-tokenized-deposit-solution-dcjpy-launches-into-production/   New Regulatory Sandbox “Project Ensemble” Unveiled by Hong Kong Markets Authority: https://www.coindesk.com/policy/2024/08/28/hong-kong-markets-authority-opens-its-tokenization-sandbox-and-major-institutions-dive-in/   Superstate Jumps in on Grand Prix Tokenization Race by Sky/ MakerDAO: https://www.sygnum.com/news/sygnum-issues-industry-first-50m-bitcoin-backed-syndicated-loan-to-ledn/   Polymesh Becomes Preferred Blockchain for RWAs for AlphaPoint: https://alphapoint.com/press/alphapoint-integrates-polymesh-as-blockchain-of-choice-for-tokenization-of-real-world-assets/   Assetera to List Tokenized Assets on EU Regulated Metapolitan Marketplace: https://www.linkedin.com/posts/thomas-labenbacher-605a235_tokenization-securitytoken-digitalsecurities-activity-7234933332126429184-ZiOW   Dinari Expands Tokenized Equities ‘dShares' on Base Blockchain: https://dinari.com/blog/dinari-dshares-now-live-on-base   Token Launchpad FractionZ to Support RWA Projects on Zchains: https://markets.businessinsider.com/news/stocks/introducing-fractionz-the-first-token-launchpad-on-zchains-1033727497   Allo and Jagad Team Up to Tokenize Indonesian Real Estate: https://newzchain.com/allo-makes-strategic-partnership-with-jagad-for-2-billion-in-rwas/   = Check out our Companies = Security Token Group: http://securitytokengroup.com/   Security Token Advisors: http://www.securitytokenadvisors.com/   Security Token Market: https://stm.co  InvestReady: https://www.investready.com   ⏰ TABLE OF CONTENTS ⏰ 0:16 Introduction 0:45 STS Interviews: ProvLabs and Nav Lend 16:23 Market Movements 31:26 STS Interviews: Maple 40:25 The Token Debrief 48:11 STS Interviews: REtokens 1:03:11 Companies of The Week: Morpho Labs and Centrifuge

In this episode, Laszlo Szabo, CEO and Co-Founder of Kiln, and Paul Frambot, CEO and Co-Founder of Morpho Labs, discuss Paul's journey of building the Morpho protocol, a lending and borrowing protocol on Ethereum. Paul explains how Morpho started as an optimization layer for Aave and Compound, but eventually built its own independent protocol called Morpho Blue.Paul highlights the inefficiencies, lack of transparency, and lack of resilience in the traditional financial industry, and how blockchain technology can address these issues. He also discusses the importance of decentralized trust and the potential for social networks in the DeFi space.Paul envisions a future where different DeFi use cases, such as decentralized exchanges, stablecoins, lending, staking, and social networks, coexist and cooperate on the blockchain.